Skip to main
ALZN
ALZN logo

Alzamend Neuro (ALZN) Stock Forecast & Price Target

Alzamend Neuro (ALZN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alzamend Neuro Inc has demonstrated significant progress in its clinical development, as evidenced by positive top-line results reported in June 2023, which bolsters confidence in its pipeline of novel therapeutic candidates for neurodegenerative diseases such as Alzheimer's. The company's current valuation appears attractive based on a net present value (NPV) analysis, suggesting potential for substantial upside from its existing share price. Furthermore, the anticipation of achieving key milestones and the ongoing generation of positive data are expected to serve as crucial catalysts for future stock appreciation.

Bears say

Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which significantly exceeded earlier estimates of $(0.69), indicating financial deterioration. The company faces substantial risks regarding its product candidates, including the potential inability to demonstrate safety and efficacy in clinical trials, as well as challenges related to regulatory approvals and commercialization. Additionally, the company is exposed to liquidity risks and external market factors, which could adversely impact investor sentiment and the overall viability of its operations in the competitive biopharmaceutical sector.

Alzamend Neuro (ALZN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alzamend Neuro (ALZN) Forecast

Analysts have given Alzamend Neuro (ALZN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Alzamend Neuro (ALZN) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alzamend Neuro (ALZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.